Sun gets final USFDA nod for Alzheimer drug

Sun Pharmaceutical Industries today announced that the US Food and Drug Aadministration (FDA) has granted it final approval for the abbreviated new drug application (ANDA) to market its generic version of Novartis's Exelon.

Sun's generic drug is equivalent to Novartis Exelon capsules, which is avaliable in four strengths. Exelon has annual sales of approximately $200 million in the US. Sun Pharma shares a 180-day marketing exclusivity for the drug.

The drug, rivastgmine tartrate, is used in treatment of mild  to moderate dementia associated with Alzheimer's diease and mild to moderate dementia associated with Parkinson's disease.